You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥疫苗首發第三期臨床結果 保護率逾70%
阿思達克 05-27 09:29
國際醫學期刊《美國醫學會雜誌》(JAMA)昨日(26日)刊登國藥集團中國生物發表的《兩種新型冠狀病毒滅活疫苗對成人COVID-19感染的保護效力評價》。研究結果顯示,中國生物兩款新冠滅活疫苗兩針接種後14天,能產生高滴度抗體,形成有效保護,且全人群中和抗體陽轉率達99%以上。「WIV04」疫苗組保護效力為72.8%,「HB02」疫苗組的保護效力為78.1%。

報告根據中國生物新冠滅活疫苗三期臨床試驗結果,總結分析中國生物所屬北京生物製品研究所(BIBP)、武漢生物製品研究所(WIBP)新冠滅活疫苗的有效性、安全性等三期臨床試驗結果,為全球首個正式發表的新冠滅活疫苗三期臨床試驗結果,亦為中國新冠疫苗三期臨床試驗結果的首次發表。

國藥疫苗第三期臨床試驗於去年7月中至12月底在阿聯酋及巴林進行,共4萬多人參與,全為18歲或以上人士,平均年齡約36歲,兩劑接種時間相隔21日。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account